Khemis A, et al. - In this 52-week prospective randomized placebo-controlled study, researchers contrasted the effectiveness of apremilast in combination therapy with narrowband (NB)-UVB vs placebo and NB-UVB treatment for repigmentation in patients with nonsegmental vitiligo. Apart from phototherapy, group A received apremilast at the label dosage and group B received placebo. Eighty adult patients with vitiligo were randomized (40 in each group). After another 24 weeks of treatment, no statistically significant differences were observed between the two groups (group A & B). Apremilast does not give NB-UVB any advantage in the treatment of vitiligo.